Autologous MSC-Derived Neural Precursors for MS Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis (MS) are largely ineffective in reversing or halting the progressive neurodegeneration and demyelination associated with the disease, with existing therapies mainly focusing on immunomodulation during the relapsing-remitting phase, leaving a need for therapies that promote neural repair and regeneration.
Innovation Solution
The use of autologous mesenchymal stem cell-derived neural precursors, which are differentiated in vitro and administered intrathecally, to promote neural repair and regeneration by differentiating into oligodendroglial and neuronal cells, reducing inflammation, and supporting damaged cells, thereby addressing the neurodegenerative aspects of MS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunomodulatory and immunosuppressive therapies are used to treat relapsing-remitting MS, then inflammation-mediated symptoms are improved, but neurodegenerative progression in secondary progressive MS is not effectively addressed
Solution Approach 1:
The patent applies universality by using mesenchymal stem cells that can perform multiple functions: they differentiate into neural progenitors for remyelination, provide immunomodulatory effects to reduce inflammation, and support neuroprotection. This single therapeutic approach addresses both the inflammatory and neurodegenerative aspects of MS, making the treatment versatile across different disease phases and forms.
Solution Approach 2:
The patent employs parameter changes by transitioning from using standard immunomodulatory drugs to using stem cell-derived neural progenitors with可调 properties. The differentiation state, cell dosage, and administration timing can be adjusted to target different disease manifestations, allowing the therapy to adapt to varying disease severity and progression stages.
2Adaptability or versatility
If embryonic stem cells are used for neural repair, then regenerative potential is improved, but transplant rejection and teratoma formation risks increase
Solution Approach 1:
The patent extracts the beneficial neural differentiation potential from stem cells while removing the harmful aspects by using mesenchymal stem cells instead of embryonic stem cells. The mesenchymal stem cells are differentiated into neural progenitors in vitro before transplantation, extracting only the needed neural repair function while eliminating the risk of teratoma formation and reducing rejection risk through autologous sourcing.
Solution Approach 2:
The patent uses an intermediary approach by introducing mesenchymal stem cells as a intermediate cell type that can be safely differentiated into neural progenitors. These intermediate cells serve as a bridge between the patient's own cells and the needed neural repair function, avoiding the direct use of problematic embryonic stem cells while still achieving the desired regenerative effect.
3Object-affected harmful factors
If adult neural stem cells are used for treatment, then immune rejection is reduced through autologous sourcing, but isolation difficulty and limited expansion capability worsen
Solution Approach 1:
The patent applies inversion by reversing the traditional approach: instead of isolating neural stem cells directly from the patient's brain tissue (which is difficult and limited), it uses easily accessible bone marrow-derived mesenchymal stem cells and differentiates them into neural progenitors in vitro. This inverted approach makes cell sourcing easier while maintaining autologous advantages.
Solution Approach 2:
The patent uses parameter changes by altering the cell source from neural tissue to bone marrow, and changing the differentiation state from undifferentiated neural stem cells to committed neural progenitors. These parameter changes improve ease of manufacture while preserving the therapeutic benefits of autologous cells.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types.